Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan introduces generic Intunivt tablets in US to treat ADHD
The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat
The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat
The intellectual property related to the panel will also be obtained by the company. Upon execution of the license, Genmab will make a one-time $4m licensing payment to
The recommendation for this combination follows a review by the NHS and Care Excellence (NICE). The combination therapy is indicated for patients with non-small cell lung cancer (NSCLC)
Perrigo will acquire rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. Novartis’s cold sore management products in the EEA and cold and
Researchers from both the parties will initially focus on canine malignant melanoma, or skin cancer, and test Nuovo’s new anti-cancer peptide drug MMX for its ability to treat
The companies will conduct clinical trials to evaluate the combination of Dynavax’s investigational toll-like receptor 9 (TLR9) agonist SD-101, with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) and its investigational
The Israeli company was first to file, making the product eligible for 180 days of market exclusivity. Risedronate sodium tablets, USP are the second approved product indicated to
The agency has granted priority review for this sBLA and is expected to respond by 30 September. The new application is based on data from CheckMate -069, the
As part of the transaction, Actavis will pay Auden £306m in cash and two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products. Actavis
Around 160 men aged 18 to 64 with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone will be included in the randomized, double-blind, placebo-controlled, parallel